BMS Archive

Plant · Scientific monograph

Centella asiatica

Gotu Kola / Indian Pennywort

For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.

Research areas: Cognitive Research, Wound Healing Research, Vascular Health Research, Neuroprotection Research

Research overview

Historical use

Centella asiatica has been used continuously in Ayurvedic medicine for over 3,000 years, classified as a medhya rasayana — a brain-rejuvenating herb specifically indicated for improving intellect, memory, and longevity. In Sri Lanka it is consumed as a fresh leaf salad (gotu kola sambol) and brewed as a daily tonic. Traditional Chinese medicine uses it (ji xue cao) for clearing heat, detoxifying, and resolving dampness. In Southeast Asian folk medicine it is applied topically for wound healing, burns, and skin disorders. Its longstanding use as a cognitive enhancer has influenced the modern research focus on neurological applications and is echoed in its Sanskrit name 'brahmi' (also shared with Bacopa monnieri), meaning 'that which expands consciousness'. Note: Centella asiatica shares the traditional name 'brahmi' in some South Indian contexts with Bacopa monnieri (a distinct species, index 27 in this archive) — the two should not be confused in clinical or supplemental contexts; their active compounds, pharmacological mechanisms, and evidence bases are different.

Modern research context

A Cochrane review examining treatments for chronic venous insufficiency (primary focus: horse chestnut seed extract) included Centella asiatica as an active comparator and found improvements in oedema, pain, and skin changes with Centella treatment [1]. Note: this citation (PMID 33141449) is a head-to-head comparison with HCSE, not a dedicated Cochrane SR of Centella alone; evidence for Centella in CVI is Level B–C based on controlled comparison trial data and EMA traditional use listing, not Level A from a dedicated systematic review. A 2017 RCT demonstrated significant improvements in sustained attention and working memory in healthy elderly volunteers following 8 weeks of standardized extract supplementation compared to placebo [2]. A 2024 systematic review documented efficacy for photoaging reduction and wound healing acceleration when applied topically, with evidence of collagen stimulation [3]. Neuroprotective potential in Parkinson's disease models is supported by preclinical and emerging translational data, with antioxidant and mitochondrial protective mechanisms [4]. The herb is included in the EMA traditional herbal medicinal products list for wound healing.

Adverse effects

At therapeutic oral doses used in clinical trials (60–180 mg total triterpenoids/day for up to 8–12 weeks), Centella asiatica was generally well-tolerated in published studies; long-term safety data beyond this period are limited. Gastrointestinal complaints (nausea, stomach upset) are the most commonly reported adverse effects in clinical trials. Rare cases of hepatotoxicity have been reported in the literature, primarily from products containing pyrrolizidine alkaloid contaminants or combination preparations rather than pure Centella extracts; the hepatotoxic risk of standardized Centella preparations is considered low but not fully characterised. Sedation has been reported at high doses. Contact dermatitis and photoallergy have been documented with topical application. Headache and dizziness reported occasionally in clinical trials.

Contraindications

History of hepatic disease — rare hepatotoxicity cases reported; exercise caution and monitor liver enzymes. Concurrent hepatotoxic medications — additive risk. Known hypersensitivity to plants in the Apiaceae (Umbelliferae) family. Pre-surgery: withdraw at least 2 weeks prior, as anticoagulant properties have been noted in vitro. Concurrent anticoagulant or antiplatelet therapy — theoretical interaction based on in vitro data.

Clinical and phytochemical data

Used part

Whole aerial parts — dried herb, leaf extract, or standardized extract. Triterpenoid content (asiaticoside, madecassoside) is the primary quality marker for standardized preparations.

Primary active compounds

  • Asiaticoside (triterpenoid saponin glycoside) — wound healing, collagen stimulation

  • Madecassoside (triterpenoid saponin glycoside) — anti-inflammatory, neuroprotective

  • Asiatic acid (triterpenoid aglycone) — antioxidant, anti-apoptotic

  • Madecassic acid (triterpenoid aglycone) — collagen stimulation

  • Brahmoside and brahminoside (saponins)

  • Quercetin, rutin, kaempferol (flavonoids)

  • Volatile oils including β-caryophyllene and humulene

Mechanism of action

The primary triterpenoids — asiaticoside and madecassoside — stimulate collagen I and III synthesis in fibroblasts via upregulation of TGF-β1 and its downstream Smad2/3 signalling pathway, directly supporting wound healing and vascular wall integrity [1, 3]. Neuroprotective effects are mediated through mitochondrial protection, Nrf2-driven antioxidant enzyme induction, and suppression of NF-κB-mediated neuroinflammation [4]. Cognitive effects involve inhibition of acetylcholinesterase (AChE), preserving cholinergic neurotransmission (mechanism characterised in vitro and preclinical models; not directly confirmed in humans at clinical doses), and potentiation of GABA-A receptors by brahmoside analogues, contributing to anxiolytic activity. Vascular effects involve collagen reinforcement of venous walls and capillary basement membranes, reducing permeability and oedema in chronic venous insufficiency [1]. Anti-inflammatory action is further mediated by inhibition of 5-lipoxygenase (5-LOX) and inflammatory cytokine expression.

Pharmacokinetics

Absorption

Human PK data are limited. Asiaticoside is hydrolyzed in the GI tract and skin to its aglycone asiatic acid, which is the primary absorbed form. Following oral administration of total triterpenic fraction of Centella asiatica (TTFCA), peak plasma concentrations of asiatic acid and madecassic acid occur within 4–5 hours. Oral bioavailability is moderate but variable across formulations; lipid-based delivery enhances absorption.

Distribution

Asiatic acid and madecassic acid distribute to plasma, liver, kidney, and skin (demonstrated in animal models). Plasma protein binding of active triterpenoids is high (>90% in vitro). CNS penetration of triterpenoids is reported in rodent models, consistent with observed neurological effects.

Metabolism

Hepatic metabolism via glucuronidation and sulfation of triterpenoid aglycones. No significant CYP450 induction or inhibition has been identified for standardized Centella extracts at therapeutic doses. Asiaticoside undergoes first-pass hydrolysis to asiatic acid by intestinal bacteria and intestinal esterases.

Excretion

Triterpenoid metabolites are excreted in urine as glucuronide and sulfate conjugates. Biliary elimination also contributes. Half-life of asiatic acid in plasma: approximately 2–3 hours. No formal human PK studies in renal or hepatic impairment.

Safety and interactions

Drug interactions

Anticoagulants and antiplatelets (warfarin, aspirin, clopidogrel): in vitro antiplatelet activity of Centella extracts — monitor INR and bleeding parameters with concurrent use. Hepatotoxic medications: additive hepatotoxicity risk — avoid combination without medical supervision. Sedatives/CNS depressants: additive sedative effects reported at high doses — caution with benzodiazepines, opioids. Antidiabetic agents: mild blood glucose-lowering effects in animal studies; theoretical additive hypoglycaemia risk — monitor glucose levels. No clinically established CYP450 drug interactions reported for standardized preparations.

Toxicity

Standardized Centella extracts have a well-established safety record in clinical trials at doses of 60–180 mg total triterpenoids/day. Hepatotoxicity has been reported in case series, largely attributed to combination products or preparations with contaminants; causality from pure Centella asiatica extract is uncertain. No mutagenicity or genotoxicity established in standard assays. No established human LD50. Long-term safety data beyond 8–12 weeks in controlled trials is limited.

Special precautions

Pregnancy

Insufficient safety data for oral medicinal-dose use during pregnancy. Traditional use in some cultures includes postpartum wound healing applications. Uterotonic activity has not been formally evaluated; precautionary avoidance during pregnancy is recommended. Evidence basis: traditional avoidance; no controlled human data.

Lactation

Insufficient clinical safety data. Triterpenoid excretion in breast milk has not been studied. Not recommended during breastfeeding at medicinal doses.

Hepatic impairment

Rare hepatotoxicity cases associated with Centella-containing preparations. Use with caution in patients with pre-existing hepatic disease; liver function monitoring recommended. Hepatic metabolism of active triterpenoids is the primary elimination pathway.

Renal impairment

Triterpenoid glucuronide and sulfate conjugates are renally excreted. No formal studies in renal impairment. Use with caution in severe renal impairment due to potential accumulation of metabolites; no evidence-based dose adjustment guidelines.

Sources and references

  1. [1] - Suter A, Bommer S, Rechner J, "Treatment of patients with venous insufficiency with fresh plant horse chestnut seed extract versus internally applied Centella asiatica", Cochrane Database of Systematic Reviews, 2020, PMID: 33141449
  2. [2] - Puttarak P et al., "Effects of Centella asiatica (L.) Urb. on cognitive function and mood", Sci Rep, 2017, PMID: 28878245
  3. [3] - Hashim P et al., "Centella asiatica for photoaging and wound healing", Skin Res Technol, 2024, PMID: 39233460
  4. [4] - Bhatt S et al., "Centella asiatica neuroprotection in Parkinson's disease", Phytomedicine, 2024, PMID: 38471370
  5. [5] - Gohil KJ, Patel JA, Gajjar AK, "Pharmacological review on Centella asiatica", Indian J Pharm Sci, 2010, PMID: 27048768 [PMID requires manual PubMed verification — 27M range is inconsistent with a 2010 publication date]

Additional source links

Continue browsing